Alicia Alpuente
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alicia Alpuente has a total of 263 co-authors. Here are the top co-authors by number of shared publications:
- Patricia Pozo-Rosich
Headache Unit, Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain
30 shared publications - Marta Torres-Ferrus
Headache and Neurological Pain Research Group, Vall d’Hebron Research Institute, Department of Neuroscience, Universitat Autònoma de Barcelona, Barcelona, Spain
23 shared publications - Edoardo Caronna
Headache and Neurological Pain Research Group, Vall d’Hebron Research Institute, Department of Neuroscience, Universitat Autònoma de Barcelona, Barcelona, Spain
22 shared publications - Victor José Gallardo
Headache and Neurological Pain Research Group, Vall d’Hebron Research Institute, Department of Neuroscience, Universitat Autònoma de Barcelona, Barcelona, Spain
18 shared publications - Raffaele Ornello
Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy
6 shared publications - Simona Sacco
Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy
6 shared publications
Latest Publications
- 15 September 2026
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (9) , 2090-2102
Hormonal treatments and migraine characteristics across reproductive stages and transition to menopause: A cross‐sectional study
Background and Objectives: Hormonal treatments (HTs) are widely used among females for contraception and gynecological conditions, yet their impact on migraine phenotype remains incompletely understood. This study aimed to (1) describe HT use in a cohort of females with migraine, (2) assess migraine phenotypes across hormonal status and HT type, and (3) explore menstrual and climacteric symptoms in females with migraine HT users versus nonusers. Methods: A cross‐sectional study was conducted including females aged 18–60 years with migraine, diagnosed according to International Classification of Headache Disorders, 3rd edition, criteria who attended a tertiary headache unit in Spain. In December 2024, participants were asked to complete a structured online survey on HT use (combined oral contraceptives, progestogen‐only pills, and hormonal intrauterine devices; only considered if stable for ≥3 months), reproductive status (reproductive stage [RS] or menopause transition), and menstrual or climacteric symptoms. Data were cross‐checked with medical records and phone interviews. Age‐ and size‐matched analyses compared HT users and nonusers, and comparisons among HT types were also performed. Results: A total of 623 females responded to the survey; 509 were included in the analysis (mean age 44.3 ± 9.2 years), including 86 (17%) current HT users. Overall, migraine phenotype and preventive treatment use were comparable between HT users and nonusers, with no statistically significant differences after adjustment for multiple comparisons (all adjusted p ‐values > 0.05). Among females in the RS and regular menstrual cycles ( n = 78), menstrually‐related migraine was highly prevalent (67/78; 86%). In the RS group comparisons ( n = 109), no differences according to HT use in migraine characteristics or menstruation‐related symptoms were observed (all adjusted p ‐values > 0.05). Similarly, among females in the menopause transition ( n = 42), no differences in migraine phenotype, preventive treatments, or climacteric symptoms were observed according to HT use (all adjusted p ‐values > 0.05). Conclusions: In this real‐world cohort of females with migraine, stable HT was not clearly associated with differences in migraine phenotype or preventive treatment patterns across reproductive stages. Menstrually‐related migraine was highly prevalent, and the menopause transition represented a period of vulnerability in a subset of patients. Larger and prospective studies are needed to confirm these findings.
- 15 September 2026
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (9) , 2090-2102
Hormonal treatments and migraine characteristics across reproductive stages and transition to menopause: A cross‐sectional study
Background and Objectives: Hormonal treatments (HTs) are widely used among females for contraception and gynecological conditions, yet their impact on migraine phenotype remains incompletely understood. This study aimed to (1) describe HT use in a cohort of females with migraine, (2) assess migraine phenotypes across hormonal status and HT type, and (3) explore menstrual and climacteric symptoms in females with migraine HT users versus nonusers. Methods: A cross‐sectional study was conducted including females aged 18–60 years with migraine, diagnosed according to International Classification of Headache Disorders, 3rd edition, criteria who attended a tertiary headache unit in Spain. In December 2024, participants were asked to complete a structured online survey on HT use (combined oral contraceptives, progestogen‐only pills, and hormonal intrauterine devices; only considered if stable for ≥3 months), reproductive status (reproductive stage [RS] or menopause transition), and menstrual or climacteric symptoms. Data were cross‐checked with medical records and phone interviews. Age‐ and size‐matched analyses compared HT users and nonusers, and comparisons among HT types were also performed. Results: A total of 623 females responded to the survey; 509 were included in the analysis (mean age 44.3 ± 9.2 years), including 86 (17%) current HT users. Overall, migraine phenotype and preventive treatment use were comparable between HT users and nonusers, with no statistically significant differences after adjustment for multiple comparisons (all adjusted p ‐values > 0.05). Among females in the RS and regular menstrual cycles ( n = 78), menstrually‐related migraine was highly prevalent (67/78; 86%). In the RS group comparisons ( n = 109), no differences according to HT use in migraine characteristics or menstruation‐related symptoms were observed (all adjusted p ‐values > 0.05). Similarly, among females in the menopause transition ( n = 42), no differences in migraine phenotype, preventive treatments, or climacteric symptoms were observed according to HT use (all adjusted p ‐values > 0.05). Conclusions: In this real‐world cohort of females with migraine, stable HT was not clearly associated with differences in migraine phenotype or preventive treatment patterns across reproductive stages. Menstrually‐related migraine was highly prevalent, and the menopause transition represented a period of vulnerability in a subset of patients. Larger and prospective studies are needed to confirm these findings.
- Open Access
- 25 June 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (6) , e70654
Erenumab and OnabotulinumtoxinA in Chronic Migraine: A Comparative Analysis
Objectives: To compare response (reduction in headache frequency and differences in patient‐reported outcomes) between Erenumab and OnabotulinumtoxinA from two phase‐IV trials after 6 months of treatment. Materials/Methods: A prospective cohort study included two parallel cohorts of chronic migraine patients treated with either Erenumab 140 mg/month or OnabotulinumtoxinA 195 U every 3 months. Participants had no additional preventive therapies or comorbid psychiatric or chronic pain conditions. Baseline data collected included demographics, monthly headache (MHD) and migraine days (MMD), impact scales (MIDAS, HIT‐6, MSQ), and anxiety/depression scores (BAI, BDI‐II). Assessments were repeated at 6 months. Baseline characteristics were balanced. Efficacy analysis (measured by reduction in MHD/MMD and impact scales) was conducted using paired t ‐test, and linear regression models compared treatment‐related changes between groups. Results: A total of 114 patients were analyzed (57 per group), with no significant baseline differences. Both treatments produced significant reductions in headache frequency at 6 months (Erenumab: −7.93 MHD and −5.36 MMD, p < 0.001; OnabotA: −6.00 MHD and −4.31 MMD, p < 0.001), without statistically significant differences between therapies. Significant improvements were observed in HIT‐6 and MSQ scores in both cohorts ( p < 0.05). The Erenumab group showed significant reductions in MIDAS, BDI, and BAI scores ( p < 0.05). Differences between treatments were significant for MIDAS improvements at three and 6 months ( p < 0.05). Conclusion: Erenumab and OnabotulinumtoxinA are effective preventive treatments for chronic migraine. No significant differences were found in the magnitude of headache reduction at 3 or 6 months when comparing both treatments.
- 25 June 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (6) , e70654
Open AccessErenumab and OnabotulinumtoxinA in Chronic Migraine: A Comparative Analysis
Objectives: To compare response (reduction in headache frequency and differences in patient‐reported outcomes) between Erenumab and OnabotulinumtoxinA from two phase‐IV trials after 6 months of treatment. Materials/Methods: A prospective cohort study included two parallel cohorts of chronic migraine patients treated with either Erenumab 140 mg/month or OnabotulinumtoxinA 195 U every 3 months. Participants had no additional preventive therapies or comorbid psychiatric or chronic pain conditions. Baseline data collected included demographics, monthly headache (MHD) and migraine days (MMD), impact scales (MIDAS, HIT‐6, MSQ), and anxiety/depression scores (BAI, BDI‐II). Assessments were repeated at 6 months. Baseline characteristics were balanced. Efficacy analysis (measured by reduction in MHD/MMD and impact scales) was conducted using paired t ‐test, and linear regression models compared treatment‐related changes between groups. Results: A total of 114 patients were analyzed (57 per group), with no significant baseline differences. Both treatments produced significant reductions in headache frequency at 6 months (Erenumab: −7.93 MHD and −5.36 MMD, p < 0.001; OnabotA: −6.00 MHD and −4.31 MMD, p < 0.001), without statistically significant differences between therapies. Significant improvements were observed in HIT‐6 and MSQ scores in both cohorts ( p < 0.05). The Erenumab group showed significant reductions in MIDAS, BDI, and BAI scores ( p < 0.05). Differences between treatments were significant for MIDAS improvements at three and 6 months ( p < 0.05). Conclusion: Erenumab and OnabotulinumtoxinA are effective preventive treatments for chronic migraine. No significant differences were found in the magnitude of headache reduction at 3 or 6 months when comparing both treatments.
- 23 June 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (12) , e214945
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine
- 23 June 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (12) , e214945
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine
- Open Access
- 19 June 2026
- Published by SAGE Publications in Cephalalgia
- Vol. 46 (6)
Is achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: Insights from the EUREkA cohort
Background: The International Headache Society has proposed new treatment goals for migraine prevention in real world, as a way to set higher standards of care. This study provides the first assessment of the proportion of individuals achieving them after 6 months of migraine-specific treatment with anti-CGRP monoclonal antibodies (MAbs). Methods: This was a prospective, real-world, European multicenter study, including adults with migraine treated with anti-CGRP MAbs (EUREkA cohort). We assessed the proportions of individuals in each treatment goal category–migraine freedom (no monthly migraine days [MMD]); optimal control (< 4 MMD), modest control (4–6 MMD); insufficient control (>6 MMD)–after 6 months of treatment. We also assessed the proportion of individuals with ≥50% reduction in MMD in the insufficient control group. Results: Of the 5818 individuals in the EUREkA cohort, 4963 had 6 months data. Of these, 82.3% (4086/4963) were females and the median age was 48.0 [40.0–55.0] years. At baseline, the median monthly headache days [MHD] and MMD were 20.0 [13.3–28.0] and 15.0 [10.0–20.0], respectively. All participants were classified as having insufficient headache control (>6 MMD) at baseline. At month 6, 6.9% (342/4963) had migraine freedom, 22.9% (1137/4963) optimal control, 24.6% (1223/4963) modest control and 45.6% (2261/4963) insufficient control. In the insufficient control group, 27.1% (613/2261) had ≥50% reduction in MMD. Conclusions: High standards of care, defined as optimal disease control or even migraine freedom, are achieved in real-world settings with anti-CGRP MAbs in approximately 30% of individuals with a high migraine burden. These findings highlight the need to expand global access to these treatments. Future studies should explore whether initiating migraine-specific preventive treatments earlier could further reduce residual migraine days in responders, enabling a larger proportion of patients to achieve optimal disease control.
- 19 June 2026
- Published by SAGE Publications in Cephalalgia
- Vol. 46 (6)
Open AccessIs achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: Insights from the EUREkA cohort
Background: The International Headache Society has proposed new treatment goals for migraine prevention in real world, as a way to set higher standards of care. This study provides the first assessment of the proportion of individuals achieving them after 6 months of migraine-specific treatment with anti-CGRP monoclonal antibodies (MAbs). Methods: This was a prospective, real-world, European multicenter study, including adults with migraine treated with anti-CGRP MAbs (EUREkA cohort). We assessed the proportions of individuals in each treatment goal category–migraine freedom (no monthly migraine days [MMD]); optimal control (< 4 MMD), modest control (4–6 MMD); insufficient control (>6 MMD)–after 6 months of treatment. We also assessed the proportion of individuals with ≥50% reduction in MMD in the insufficient control group. Results: Of the 5818 individuals in the EUREkA cohort, 4963 had 6 months data. Of these, 82.3% (4086/4963) were females and the median age was 48.0 [40.0–55.0] years. At baseline, the median monthly headache days [MHD] and MMD were 20.0 [13.3–28.0] and 15.0 [10.0–20.0], respectively. All participants were classified as having insufficient headache control (>6 MMD) at baseline. At month 6, 6.9% (342/4963) had migraine freedom, 22.9% (1137/4963) optimal control, 24.6% (1223/4963) modest control and 45.6% (2261/4963) insufficient control. In the insufficient control group, 27.1% (613/2261) had ≥50% reduction in MMD. Conclusions: High standards of care, defined as optimal disease control or even migraine freedom, are achieved in real-world settings with anti-CGRP MAbs in approximately 30% of individuals with a high migraine burden. These findings highlight the need to expand global access to these treatments. Future studies should explore whether initiating migraine-specific preventive treatments earlier could further reduce residual migraine days in responders, enabling a larger proportion of patients to achieve optimal disease control.
- Open Access
- 16 May 2026
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 27 (1)
Brain structural MRI changes before and after 6 months of preventive treatment with erenumab and onabotulinumtoxinA in migraine
Structural neuroimaging findings in migraine remain heterogeneous, and the impact of preventive treatments such as erenumab and onabotulinumtoxinA (OnabotA
- 16 May 2026
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 27 (1)
Open AccessBrain structural MRI changes before and after 6 months of preventive treatment with erenumab and onabotulinumtoxinA in migraine
Structural neuroimaging findings in migraine remain heterogeneous, and the impact of preventive treatments such as erenumab and onabotulinumtoxinA (OnabotA
- Open Access
- 14 May 2026
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 27 (1)
Multimodal serum and MRI signatures of neuroaxonal injury in high-frequency migraine
It remains unclear whether high-frequency migraine is associated with objective markers of possible neuroaxonal injury and potential expression of neurodeg
- 14 May 2026
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 27 (1)
Open AccessMultimodal serum and MRI signatures of neuroaxonal injury in high-frequency migraine
It remains unclear whether high-frequency migraine is associated with objective markers of possible neuroaxonal injury and potential expression of neurodeg
- Top Cited Papers
- 24 February 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (4) , e214659
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine
The aim of this study was to describe the long-term effectiveness and treatment persistence of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (MAbs) in migraine and to identify baseline factors associated with 2-year treatment continuation. A prospective observational multicenter registry-based study of anti-CGRP MAbs was conducted. We analyzed changes in monthly headache days (MHDs) at 24 months (M24) compared with baseline in those who reached M24 (ON-group). We analyzed patterns of response at 4 time points (6, 12, 18, and 24 months). We defined sustained response (SR) as a ≥50% reduction in MHDs at ≥3 of 4 time points. We compared baseline characteristics of the ON-group with those of the discontinuation group because of lack of effectiveness (OFF-group). A total of 1,340 individuals reached M24 (ON-group: median age 48.0 [41.0-55.0] years; 81.7% female). The median MHD at baseline was 20.0 (13.0-28.0) days. At M24, 60.4% of patients demonstrated ≥50% reduction in MHDs (809/1,340). The proportion of participants achieving SR at M24 was 53.8% (142/264). When compared with the ON-group (n = 1,340), the OFF-group (n = 1,057) showed statistically significant higher baseline MHDs (ON: 20.0 [13.0-28.0] vs OFF: 25.0 [16.0-28.0]) and a greater proportion of patients with aura (ON: 16.2% vs OFF: 22.9%), depression (ON: 22.8% vs OFF: 37.9%), and obesity (ON: 7.2% vs OFF: 19.1%) (p < 0.001). Sustained reductions in MHDs to anti-CGRP treatment at 2 years was observed. Delayed treatment onset, migraine with aura, depression, and obesity may negatively affect treatment persistence. This study provides Class IV evidence that, in patients with migraine, treatment with anti-CGRP MAbs is associated with sustained reductions in MHDs over a 24-month period.
- 24 February 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (4) , e214659
Top Cited PapersLong-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine
The aim of this study was to describe the long-term effectiveness and treatment persistence of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (MAbs) in migraine and to identify baseline factors associated with 2-year treatment continuation. A prospective observational multicenter registry-based study of anti-CGRP MAbs was conducted. We analyzed changes in monthly headache days (MHDs) at 24 months (M24) compared with baseline in those who reached M24 (ON-group). We analyzed patterns of response at 4 time points (6, 12, 18, and 24 months). We defined sustained response (SR) as a ≥50% reduction in MHDs at ≥3 of 4 time points. We compared baseline characteristics of the ON-group with those of the discontinuation group because of lack of effectiveness (OFF-group). A total of 1,340 individuals reached M24 (ON-group: median age 48.0 [41.0-55.0] years; 81.7% female). The median MHD at baseline was 20.0 (13.0-28.0) days. At M24, 60.4% of patients demonstrated ≥50% reduction in MHDs (809/1,340). The proportion of participants achieving SR at M24 was 53.8% (142/264). When compared with the ON-group (n = 1,340), the OFF-group (n = 1,057) showed statistically significant higher baseline MHDs (ON: 20.0 [13.0-28.0] vs OFF: 25.0 [16.0-28.0]) and a greater proportion of patients with aura (ON: 16.2% vs OFF: 22.9%), depression (ON: 22.8% vs OFF: 37.9%), and obesity (ON: 7.2% vs OFF: 19.1%) (p < 0.001). Sustained reductions in MHDs to anti-CGRP treatment at 2 years was observed. Delayed treatment onset, migraine with aura, depression, and obesity may negatively affect treatment persistence. This study provides Class IV evidence that, in patients with migraine, treatment with anti-CGRP MAbs is associated with sustained reductions in MHDs over a 24-month period.
- Open Access
- 16 April 2025
- Published by SAGE Publications in Cephalalgia
- Vol. 45 (4)
Effectiveness of anti-CGRP monoclonal antibodies and onabotulinumtoxinA in menstrually-related migraine: The unmet need of perimenstrual headache days
Background: Data on the effectiveness of preventive treatments on menstrually-related migraine (MRM) is scarce. Our objective was to analyze the efficacy of anti-calcitonin gene-related peptide monoclonal antibodies (anti-CGRP mAbs) and onabotulinumtoxinA (BTX-A) in the reduction of perimenstrual headache days (PHD) and perimenstrual migraine days (PMD) compared to non-perimenstrual headache days (non-PHD) and non-perimenstrual migraine days (non-PMD) per month in women with MRM. Methods: A retrospective study was conducted including females with menstruation and headache records, treated with either anti-CGRP mAbs or BTX-A. Patients completed e-Diary one month before and three months after preventive treatment. We collected clinical data and analyzed PHD/PMD and non-PHD/non-PMD before and after treatment. Additional analyses included PHD/PMD and non-PHD/non-PMD comparisons grouped by aura, episodic/chronic migraine, treatment and contraceptive intake. Results: We analyzed data from 113 females with a median (range) age of 39.0 (33.0–45.0) years. When combining patients treated with anti-CGRP mAbs or BTX-A, a median (range) of 2.0 (2.0–3.0) PHD/month (corresponding to 13.6% baseline monthly headache days (MHD)) and 13.0 (9.0–17.0) non-PHD/month pre-treatment was observed. From these, 2.0 (1.0–3.0) were PMD/month, and 7.0 (4.0–11.0) were non-PMD/month. After treatment, the median PHD/month was 2.0 (1.0–3.0) (corresponding to 16.67% of MHD) ( p = 0.085), and 8.0 (5.0–13.0) were non-PHD/month ( p < 0.001); from these, 1.0 (0.0–3.0) were PMD/month (proportion difference, p = 0.035) and 4.0 (2.0–7.0) were non-PMD (proportion difference, p < 0.001). When analyzing grouped by treatment, only patients treated with anti-CGRP experienced a reduction in PMD. No statistically significant differences in clinical factors (aura, migraine diagnosis, contraceptive intake) between PHD/non-PHD or PMD/non-PMD, either pre- or post-treatment. A higher probability risk of headache and migraine during the perimenstrual window was observed independently of the treatment received (odds ratio = 1.637, 95% confidence interval = 1.356–1.984, p < 0.001). Conclusions: Three-month treatment with anti-CGRP mAbs or BTX-A effectively reduced non-PHD and non-PMD but had limited effect on PHD/PMD because headache probability risk was higher during the perimenstrual window after treatment.
- 16 April 2025
- Published by SAGE Publications in Cephalalgia
- Vol. 45 (4)
Open AccessEffectiveness of anti-CGRP monoclonal antibodies and onabotulinumtoxinA in menstrually-related migraine: The unmet need of perimenstrual headache days
Background: Data on the effectiveness of preventive treatments on menstrually-related migraine (MRM) is scarce. Our objective was to analyze the efficacy of anti-calcitonin gene-related peptide monoclonal antibodies (anti-CGRP mAbs) and onabotulinumtoxinA (BTX-A) in the reduction of perimenstrual headache days (PHD) and perimenstrual migraine days (PMD) compared to non-perimenstrual headache days (non-PHD) and non-perimenstrual migraine days (non-PMD) per month in women with MRM. Methods: A retrospective study was conducted including females with menstruation and headache records, treated with either anti-CGRP mAbs or BTX-A. Patients completed e-Diary one month before and three months after preventive treatment. We collected clinical data and analyzed PHD/PMD and non-PHD/non-PMD before and after treatment. Additional analyses included PHD/PMD and non-PHD/non-PMD comparisons grouped by aura, episodic/chronic migraine, treatment and contraceptive intake. Results: We analyzed data from 113 females with a median (range) age of 39.0 (33.0–45.0) years. When combining patients treated with anti-CGRP mAbs or BTX-A, a median (range) of 2.0 (2.0–3.0) PHD/month (corresponding to 13.6% baseline monthly headache days (MHD)) and 13.0 (9.0–17.0) non-PHD/month pre-treatment was observed. From these, 2.0 (1.0–3.0) were PMD/month, and 7.0 (4.0–11.0) were non-PMD/month. After treatment, the median PHD/month was 2.0 (1.0–3.0) (corresponding to 16.67% of MHD) ( p = 0.085), and 8.0 (5.0–13.0) were non-PHD/month ( p < 0.001); from these, 1.0 (0.0–3.0) were PMD/month (proportion difference, p = 0.035) and 4.0 (2.0–7.0) were non-PMD (proportion difference, p < 0.001). When analyzing grouped by treatment, only patients treated with anti-CGRP experienced a reduction in PMD. No statistically significant differences in clinical factors (aura, migraine diagnosis, contraceptive intake) between PHD/non-PHD or PMD/non-PMD, either pre- or post-treatment. A higher probability risk of headache and migraine during the perimenstrual window was observed independently of the treatment received (odds ratio = 1.637, 95% confidence interval = 1.356–1.984, p < 0.001). Conclusions: Three-month treatment with anti-CGRP mAbs or BTX-A effectively reduced non-PHD and non-PMD but had limited effect on PHD/PMD because headache probability risk was higher during the perimenstrual window after treatment.
- Open Access
- 24 September 2024
- Published by SAGE Publications in Cephalalgia
- Vol. 44 (9)
Case series on monoclonal antibodies targeting calcitonin gene-related peptide in migraine patients during pregnancy: Enhancing safety data
Background: Monoclonal antibodies targeting calcitonin gene-related peptide (CGRP-mAbs) are approved for adult migraine prevention but pose safety concerns in pregnancy. We assess the safety of CGRP-mAbs in the periconceptional period through a case series and literature review. Methods: Six migraine-diagnosed women received CGRP-mAbs; treatment ceased upon pregnancy. We collected data and conducted safety assessments. To provide a comprehensive context, we performed a literature review. Results: The series includes three erenumab, two fremanezumab and one galcanezumab case. A fremanezumab recipient experienced miscarriage; severe perinatal asphyxia linked to dystocia occurred with erenumab (140 mg). Database reviews revealed 63 spontaneous abortions, eight premature births, and seven birth defects among 286 World Health Organization and 65 European Medicines Agency cases. These rates align with untreated population rates. Conclusions: CGRP-mAbs use in the periconceptional period does not lead to clinically significant increase in pregnancy-related pathology or adverse effects on newborns within our case series and the literature reviewed.
- 24 September 2024
- Published by SAGE Publications in Cephalalgia
- Vol. 44 (9)
Open AccessCase series on monoclonal antibodies targeting calcitonin gene-related peptide in migraine patients during pregnancy: Enhancing safety data
Background: Monoclonal antibodies targeting calcitonin gene-related peptide (CGRP-mAbs) are approved for adult migraine prevention but pose safety concerns in pregnancy. We assess the safety of CGRP-mAbs in the periconceptional period through a case series and literature review. Methods: Six migraine-diagnosed women received CGRP-mAbs; treatment ceased upon pregnancy. We collected data and conducted safety assessments. To provide a comprehensive context, we performed a literature review. Results: The series includes three erenumab, two fremanezumab and one galcanezumab case. A fremanezumab recipient experienced miscarriage; severe perinatal asphyxia linked to dystocia occurred with erenumab (140 mg). Database reviews revealed 63 spontaneous abortions, eight premature births, and seven birth defects among 286 World Health Organization and 65 European Medicines Agency cases. These rates align with untreated population rates. Conclusions: CGRP-mAbs use in the periconceptional period does not lead to clinically significant increase in pregnancy-related pathology or adverse effects on newborns within our case series and the literature reviewed.